Vigencell, an affiliate of Boryeong Pharmaceutical has passed the technological level test of the Korea Exchange, satisfying the requirements for fast-track listing on the KOSDAQ market, the company announced on March 22.Vigencell earned A and BBB ratings, respectively, from two professional rating
ViGenCell, a biotechnology affiliate of Boryung Pharmaceutical that specializes in immune cell therapy technologies, has launched a scientific advisory committee composed of immunological and clinical research experts to accelerate the development of treatments for intractable diseases and strengthe
The author is an analyst of Shinhan Investment Corp. He can be reached at shawn1225@shinhan.com. -- Ed. Strong in ETC market with Korea’s first hypertension drug KanarbBoryung Pharmaceutical stands out vs. other, generic drug-focused mid-tier pharmaceuticals in the domestic market, backed by its com
Boryung Pharmaceutical and Vigencell announced on Sept. 8 that they have signed an R&D agreement to develop immunocyte therapy. The agreement will pave the way for the two companies to cooperate in development and commercialization of diverse immune-cell treatments.The agreement will help Vigencell
Domestic biopharmaceutical companies are putting more efforts into research and development (R&D) to advance into the rapidly growing immune cancer drug market.Boryung Pharmaceutical started on April 23 the operation of a new production complex in the Junggok industrial complex in South Chungcheon P
Boryung Pharmaceutical is stepping up efforts to develop both biologics and chemical drugs.According to the pharmaceutical and biotechnology industry on Nov. 20, Boryung Pharma is seeking to enter the biopharmaceuticals market by developing an immune cell therapy treatment through its subsidiary Vig
Korean pharmaceutical companies are expected to develop Cancer immunotherapy drugs within a few years because some Korean companies began to accumulate and develop related technologies.More intense competition is expected in the domestic market of cancer immunotherapy drugs called “third-generation
According to industry sources on December 18, the number of domestic pharmaceutical and biotech companies that are seeking to develop cell therapy products has greatly increased. There are two primary concerns that domestic firms have. First of all, there is an outstanding boom in the development of